Serotoninergic syndrome

Two cases reported to the National Center of Pharmacovigilance (Centro Nacional de Farmacovigilancia)

Authors

  • Susana Rodríguez Universidad de la República, Facultad de Medicina, Toxicología, Asistente
  • Salomé Fernández Universidad de la República, Facultad de Medicina, Toxicología, Asistente
  • Mabel Burger Universidad de la República, Facultad de Medicina, Centro de Información y Asesoramiento Toxicológico, Profesora Directora. Centro Nacional de Farmacovigilancia, Codirectora

Keywords:

SEROTONIN SYNDROME, DRUG INTERACTIONS

Abstract

Two cases of drug interaction by antidepressive and antianxiety drugs were reported de the harmacoviligance National Center. Clinical presentation showed non-sleep alterations, neurovegetative and neuroskeletal symptoms.
Immediate withdrawal of the treatment stopped symptomatic course. Clinical manifestation might be due to serotoninergic syndrome. A discussion on diagnosis, Etiology, causes and treatment is presented.

References

1) Pentel PR, Keyler DE, Lester M. Tricyclic antidepressants and selective serotonin reuptake inhibitors. In: Haddad LM, Shannon MW, Winchester JF, eds. Clinical management of poisoning and drug overdose. 3rd ed. Philadelphia: WB Saunders, 1998: 437-51.
2) Pentel PR, Keyler DE, Lester M. Monoamine oxidase inhibitors and the serotonin syndrome. In: Haddad LM, Shannon MW, Winchester JF, eds. Clinical management of poisoning and drug overdose. 3rd ed. Philadelphia: WB Saunders, 1998: 452-63.
3) Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995; 45(2): 219-23.
4) George TP, Godleski LS. Possible serotonin syndrome with trazodone addition to fluoxetine. Biol Psychiatry 1996; 39(5): 384-5.
5) Goldberg RJ. Serotonin syndrome from trazodone and buspirone. Psychosomatics 1992; 33(2): 235-6.
6) Dursun SM, Mathew VM, Reveley MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993; 342(8868): 442-3.
7) Nisijima K, Shimizu M Abe T, Ishiguro T. A case of serotonin syndrome induced by concomitant treatment with low-dose trazodone and amitriptyline and lithium. Int Clin Psychopharmacol 1996; 11(4): 289-90.
8) Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Parkinson Study Group. Neurology 1997; 48(4): 1070- 17.
9) Gillman PK. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust 1997; 167(2): 109-11.
10) Brubacher JR. Treating the serotonin syndrome-antidote or support? J Toxicol Clin Toxicol 1997; 35(2): 213-4.

Published

2005-03-31

How to Cite

1.
Rodríguez S, Fernández S, Burger M. Serotoninergic syndrome: Two cases reported to the National Center of Pharmacovigilance (Centro Nacional de Farmacovigilancia). Rev. Méd. Urug. [Internet]. 2005 Mar. 31 [cited 2024 Sep. 16];21(1):78-82. Available from: https://revista.rmu.org.uy/index.php/rmu/article/view/839